We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Quetiapine Decreases Smoking in Patients With Chronic Schizophrenia

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2005 by Arthur P. Noyes Research Foundation.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00231101
First Posted: October 4, 2005
Last Update Posted: October 17, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Arthur P. Noyes Research Foundation
  Purpose
A single-blind switching study in which forty subjects currently being treated with risperidone will be randomly assigned to either stay on risperidone or switched to quetiapine. Various behavioral and biological measures will be used to compare smoking behavior over time in these two groups.

Condition Intervention
Smoking Behavior in Schizophrenia Drug: Quetiapine

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Educational/Counseling/Training
Official Title: Quetiapine Decreases Smoking in Patients With Chronic Schizophrenia

Resource links provided by NLM:


Further study details as provided by Arthur P. Noyes Research Foundation:

Primary Outcome Measures:
  • The Fagerstrom Test for Nicotine Dependence,weekly measures of expired CO and blood levels of cotinine. The endpoints for assessing nicotine receptor activation will include: the auditory P50, visuospatial working memory, and the CPT.
  • Changes in psychopathology will be performed monthly PANSS, CGI, and the SANS.
  • EPS will be measured weekly using the NRS, and the Barnes Akathisia Scale.

Estimated Enrollment: 40
Study Start Date: January 2004
Estimated Study Completion Date: June 2006
  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients (male or female) between 18-65 years of age must be diagnosed as having DSM-IV schizophrenia (any subtype including schizoaffective disorder).
  2. Patients must have shown a less-than-optimal clinical response to an adequate course of risperidone treatment and must be willing to agree to the possibility of receiving quetiapine as an alternative treatment for their mild to moderate psychotic symptoms. We define an adequate course of treatment as three or more months of at least 6 mg/day of risperidone. We define less-than-adequate treatment as a Total PANSS Score of 60 or more.
  3. Patients must be active cigarette smokers. We define active cigarette smoking as patients who consume one pack of cigarettes or more per day. Although there is no standard for defining active cigarette smokers, it has been our experience that the high rate of smoking activity on the hospital wards can have the effect of small elevations in cotinine levels even among “non-smoking” patients through second hand smoke. Therefore, we want to insure that we enroll “heavy” smokers.
  4. Patients must be able to fully participate in the informed consent and HIPAA process, or have a legal guardian able to participate

Exclusion Criteria:

  1. Patients who have had an adequate clinical response to risperidone and are considered by themselves or their treating psychiatrist to be clinically stable.
  2. Patients who are judged to be treatment refractory, which we define as documented treatment failure with 3 FDA-approved antipsychotic medications administered for an adequate duration in a sufficient dosage (6 or more weeks of 1000 mg/day chlorpromazine equivalents).
  3. Patients at the time of screening who have clinically significant akathisia (Barnes global score >2), Parkinsonian symptoms symptoms (Simpson Angus total score >3), or significant EPS (indicated by treatment with benztropine, lorazepam or propranolol).
  4. ECG abnormalities consistent with significant or acute cardiac disease.
  5. History of significant or unstable hypertension during the screening examination outside the range from 90/60 to 140/90, or a pulse outside of the range of 60 to 100 beats per minute.
  6. Any history of seizures or primary CNS disease (other than tardive dyskinesia or extrapyramidal symptoms from psychotropic medications), comatose states, bone marrow depression, significant cardiovascular, renal or hepatic disease, brain trauma, chronic obstructive lung disease and/or pulmonary emphysema, or a mental deficiency.
  7. Active drug or alcohol addiction within the past 3-month period.
  8. Symptoms of significant physical illness in the 4-week period prior to enrollment, excluding mild upper respiratory or gastrointestinal disorders.
  9. Clinical laboratory findings that indicate the presence of a pathological condition in the judgment of the principal investigator.
  10. Having received any investigational drug in the 4 weeks preceding the study.
  11. Pregnant or lactating patients are excluded. Pregnancy must be excluded by laboratory tests prior to beginning the study. Female patients judged to have potential for pregnancy (sexually-active females who do not use an approved form of contraception) will be excluded.
  12. At serious suicidal risk.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00231101


Contacts
Contact: Richard C Josiassen, Ph.D. richardjosiassen@noyesfoundation.net

Locations
United States, Pennsylvania
Arthur P. Noyes Research Foundation Recruiting
Norristown, Pennsylvania, United States, 19401
Contact: Richard C Josiassen, Ph.D.       richardjosiassen@noyesfoundation.net   
Principal Investigator: Richard C Josiassen, Ph.D.         
Sponsors and Collaborators
Arthur P. Noyes Research Foundation
Investigators
Principal Investigator: Richard C Josiassen, Ph.D. Arthur P. Noyes Research Foundation
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00231101     History of Changes
Other Study ID Numbers: NSH Protocol 03-08
First Submitted: September 30, 2005
First Posted: October 4, 2005
Last Update Posted: October 17, 2006
Last Verified: September 2005

Keywords provided by Arthur P. Noyes Research Foundation:
Smoking
Schizophrenia

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Quetiapine Fumarate
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs